

Recordati receives the special Award "Finance for Growth"

10th KPMG M&A AWARD

Milan (Italy), April 11th 2014 – Recordati Group was awarded the Special Award “Finance for Growth” at the 10th edition of the M&A Award, sponsored by KPMG and Fineurop Soditic, under the patronage of AIFI and Bocconi University. Each year, the Award puts the spotlight on M&A and its positive impact on growth, company size, capability to adapt to new competitive and market environments and technological upgrade. The goal is to bring to the attention of the business community those companies that are champions of excellence and that represent a reference model for national capitalism.

"Thanks to the 17 acquisitions all around the world over the past 15 years, which have contributed to the consolidation and development of the company, whose revenues grew from 214 million Euro in 1998 to 941 million in 2013" - explains the motivation - "Recordati was able to integrate M&A in its business model as an important competitive advantage factor and a growth accelerator, especially on international markets. Thanks to the acquisitions, Recordati implemented an important strategic plan of geographical diversification in high-potential markets such as Eastern Europe, Turkey, Tunisia and in the United States."

Recordati is an international pharmaceutical group, listed on the Italian Stock Exchange with a total staff of around 4,000, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey, in North Africa and in the United States of America.

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of around 4,000, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey, in North Africa and in the United States of America. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties within the urogenital therapeutic area and of treatments for rare diseases. Consolidated revenue for 2013 was € 941.6 million, operating income was € 195.4 million and net income was € 133.7 million.

For further information:

Recordati website: www.recordati.com

Investor Relations

Marianne Tatschke

(39)0248787393

e-mail: inver@recordati.it

Media Relations

Ketchum

Cristina Risciotti, (39)0262411919, cristina.risciotti@ketchum.it

Marzia Ongaretti, (39)0262411915, marzia.ongaretti@ketchum.it